Generic drugmaker Sandoz is recalling two lots of an injectable drug, making yet another manufacturing problem for its parent, Novartis.
A worker at an Amgen research facility in South San Francisco has been hospitalized after a "flash fire" involving hazardous materials.
After taking a $500 million charge against 2012 earnings for Yaz and Yasmin-related litigation, Bayer has lost its patent fight with three generics makers intent on selling their own copycats.
The news on the biosimilar R&D front has been all bad in recent months--at least for the biggest players in the business. Merck, Teva and Samsung have all experienced severe setbacks, scrapping follow-on programs for some of the biggest biologic targets now on the market.
Johnson & Johnson ($JNJ) and Novartis ($NVS) are the latest pharma companies to feel the ire of EU antitrust regulators. European Commission officials have accused the two drugmakers of delaying a generic version of the painkiller fentanyl--and violating competition laws in the process.
A drug development center in Mumbai will be reorganized out of operation as Sandoz restructures its business in India.
Sandoz is expanding its production capacity at a plant in South Africa in anticipation of a new public health initiative to provide more drugs to citizens.
Novartis appears to be swamped by questions of manufacturing quality. Manufacturing topics dominated much of the earnings discussion of Novartis CEO Joseph Jimenez with reporters Wednesday. He was defending the quality of flu vaccine which both Italy and the company's homeland of Switzerland have banned from sale after Novartis said there may be possible side effects.
Watson Pharmaceuticals is set to sell manufacturing technology for 18 drugs to meet conditions on its $5.9 billion takeover of Actavis. Par Pharmaceuticals and Sandoz are poised to snag the products, which Watson must sell to meet Federal Trade Commission conditions of its takeover.
Watson Pharmaceuticals ($WPI) and Actavis won Federal Trade Commission approval for their $5.6 billion merger. Provided, that is, that they sell off a basketful of marketed and as-yet-unapproved products, and give up marketing rights to three others.